Asychem Announces New CTO For Pioneering Small-Molecule Research

Asymchem is pleased to announce the appointment of Dr. Cheng Yi Chen as the Chief Technology Officer for its Small-Molecule Sector. In this role, Dr. Chen will directly report to Dr. Hao Hong, Asymchem's CEO. He will be instrumental in supporting the technical aspects of the group's chemical small molecule sales in Europe and the United States.

Dr. Chen's responsibilities include engaging in technical communications for significant mid-to-late-stage clinical projects in these regions and fostering collaborations with new key clients by leveraging the group's technical strengths in the small-molecule sector. Additionally, he will advise the China Core Team on technical matters related to European and US projects, offer guidance for communications, and provide technical recommendations for the Boston site. He will also oversee technical operations at small-molecule laboratories and pilot production facilities across Europe.

Before joining Asymchem, Dr. Chen gained valuable experience at Merck Research Laboratories, Janssen Pharmaceuticals of Johnson & Johnson, Mirati Therapeutics, and Bristol Myers Squibb. His expertise spans the design, development, and implementation of efficient, cost-effective, and sustainable manufacturing processes for small molecule APIs. He is skilled in ensuring compliance with CMC standards and quality requirements, collaborating with cross-functional drug development teams and external partners, and supporting regulatory submissions.